IL18 and neoplasm: Therefore, even though constitutive high expression of IL-18 can lead to greater anti-tumor activity compared with inducible systems, the ability to control IL-18 secretion should still be considered a safer alternative for enhancing the anti-tumor activity of CAR-T cells.